Nobuhiko Tamura is Sunovion's champion of drug discovery and development and primary architect of the R&D that fuels the company’s dynamic discovery and development efforts. He assumed the executive leadership role of Sunovion as Vice Chair, Board of Directors in April 2014, and also serves as the Head of Global Clinical Development for Sumitomo Dainippon Pharma Co., Ltd. Group.
Previously, as Sunovion's Chief Scientific Officer, Mr. Tamura led the submission and subsequent FDA approval of Latuda (lurasidone HCl), an atypical antipsychotic for the treatment of schizophrenia in adults. Before Sumitomo Dainippon Pharma's acquisition of Sepracor, he was the President of Dainippon Sumitomo Pharma America (DSPA).
Mr. Tamura began his career as a researcher in drug discovery at Sumitomo Chemical Co., Ltd. and was one of the first employees of Sumitomo Pharmaceutical Co., Ltd. (SP) when it became a separate subsidiary in 1984. After working for six years in SP's discovery lab, he broadened his experience as a member of a business development group in New York and served as a representative of SP America for five years before returning to Japan from 1994 to 2007. During that time, he led several biological projects within the R&D Division of SP and Sumitomo Dainippon Pharma, and fostered the development of new chemical entities for the treatment of diseases of the central nervous system, among others.
Mr. Tamura serves on the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA).
Mr. Tamura earned his Master of Pharmacy from Tohoku University and a Bachelor of Pharmacy from the Tokyo University of Science.